3M27-A2 Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. 2nd ed. 2002.22(15):1-30.
4M38-A, Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi, Approved Standard. 2002.22(16):1-30.
5Lass-florl C, Kofler G, Kropshofer G, et al. In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis. J Antimicro Chemoth, 1998,42:497-502.
6Pfaller MA, Boyken L, Hollis RJ,et al. In vitro susceptibilities of clinical isolates of Candida species, cryptococcus neoformans, and Aspergillus species to itraconazole:global survey of 9359 isolates tested by Clinical and Laboratory Standards Institute Broth Microdilution Methods. J Clin Microb ,2005,43:3807-3810.
7Willems L, van der C, eest R, de Beule K. Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics. J Clin Phar Ther, 2001,26:159-169.
8Fothergill AW, Rinaldi MG,Sutton DA. Antifungal susceptibility testing. Infect Dis Clin North Am,2006,20:699-700.
9Pfaller MA, Diekema D J, Sheehan DJ. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint of the future for antifungal susceptibility testing. Clin Microbiol Rev,2006,19:435-447.
10Rex JH,Pfaller MA. Has antifungal susceptibility testing come of age? Clin Infect Dis,2002,35:982-989.
